Alzinova AB, a Swedish biopharma company announced that the Company has reached an important milestone where the last patient in the Phase 1b study with the vaccine candidate ALZ-101 against Alzheimer’s disease has been enrolled and received his first dose.
Read the original press release: alzinova-reaches-important-milestone-phase-1b-study-fully-recruited